Stockscreener 앱 받기
3.35
8.10%
-0.29
시간 외 거래:
3.35
전일 마감가:
$3.64
열려 있는:
$3.58
하루 거래량:
677.86K
Relative Volume:
1.60
시가총액:
$96.59M
수익:
-
순이익/손실:
$-14.14M
주가수익비율:
-3.6413
EPS:
-0.92
순현금흐름:
$-12.64M
1주 성능:
-14.23%
1개월 성능:
+62.38%
6개월 성능:
+59.67%
1년 성능:
+111.71%
1일 변동 폭
$3.24
$3.58
1주일 범위
$3.24
$4.05
52주 변동 폭
$1.34
$4.05
Immix Biopharma Inc Stock (IMMX) Company Profile
명칭
Immix Biopharma Inc
전화
(888) 958-1084
주소
11400 WEST OLYMPIC BLVD., LOS ANGELES
IMMX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
3.35 | 120.25M | 0 | -14.14M | -12.64M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.33 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
627.97 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.26 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.34 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.74 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Immix Biopharma Inc 주식(IMMX)의 최신 뉴스
Immix Biopharma to present NXC-201 trial data for AL amyloidosis at ASH - Investing.com Australia
Can trapped investors hope for a rebound in Immix Biopharma Inc.2025 Momentum Check & Fast Gain Stock Tips - newser.com
How Immix Biopharma Inc. stock valuations compare to rivalsWeekly Trend Summary & Consistent Growth Equity Picks - newser.com
Why Immix Biopharma Inc. stock appeals to dividend seekersJuly 2025 Decliners & High Return Stock Watch Alerts - newser.com
How rising interest rates impact Immix Biopharma Inc. stock2025 Top Gainers & Technical Pattern Based Signals - newser.com
Immix Biopharma : Presentation (IMMX Corporate presentation November 2025) - MarketScreener
What analysts say about Immix Biopharma Inc stockTechnical Resistance Breaks & Affordable Portfolio Growth - earlytimes.in
How to manage a losing position in Immix Biopharma Inc.Trade Exit Summary & Capital Efficient Trading Techniques - newser.com
Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025 - Investing News Network
Immix Biopharma (IMMX) ASH 2025 oral to feature NEXICART-2 first 20-patient data on Dec 7 - Stock Titan
How Immix Biopharma Inc. stock reacts to bond yieldsGap Up & Free Expert Approved Momentum Trade Ideas - newser.com
Immix Biopharma Inc (IMMX) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - setenews.com
Immix Biopharma Inc. stock volume spike explainedJuly 2025 Reactions & Free Safe Capital Growth Stock Tips - newser.com
What the charts say about Immix Biopharma Inc. today2025 Analyst Calls & Safe Entry Point Identification - newser.com
Will Immix Biopharma Inc. stock sustain high P E ratiosEarnings Miss & Daily Entry Point Alerts - newser.com
Immix Biopharma Inc. stock trendline breakdownTrade Analysis Report & Daily Volume Surge Signals - newser.com
Comparing Immix Biopharma Inc. in custom built stock radarsQuarterly Portfolio Report & Reliable Breakout Forecasts - newser.com
Risk adjusted return profile for Immix Biopharma Inc. analyzedMarket Performance Recap & Risk Controlled Stock Alerts - newser.com
Is Immix Biopharma Inc. stock a smart buy before Fed meeting2025 Market Outlook & Daily Stock Momentum Reports - newser.com
Is Immix Biopharma Inc. still worth holding after the dip2025 Volume Leaders & Technical Confirmation Trade Alerts - newser.com
Will Immix Biopharma Inc. see short term momentum2025 Major Catalysts & Capital Protection Trading Alerts - newser.com
Immix Biopharma (NASDAQ:IMMX) Trading Down 1.3%Time to Sell? - MarketBeat
Momentum divergence signals in Immix Biopharma Inc. chartJuly 2025 Decliners & Daily Stock Trend Reports - newser.com
Immix Biopharma’s NXC-201 CAR-T Study: A Potential Game-Changer for AL Amyloidosis - TipRanks
Immix Biopharma Inc (IMMX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.29%
0.56%
자본화:
|
볼륨(24시간):